# China NMPA Drug Inspection - Sichuan Jingzhong Traditional Chinese Medicine Pieces Co., Ltd. - Atractylodes lancea

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/sichuan-jingzhong-traditional-chinese-medicine-pieces-co-ltd/e1d4ee8c-ce05-4cc5-a28a-20993e20110b/
Source feed: China

> China NMPA drug inspection for Sichuan Jingzhong Traditional Chinese Medicine Pieces Co., Ltd. published September 13, 2018. Drug: Atractylodes lancea. The Sichuan Provincial Food and Drug Administration issued a Drug Quality Bulletin on September 13, 2018, announcing fin

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Sichuan Province Drug Quality Bulletin (Issue 7, 2018)
- Company Name: Sichuan Jingzhong Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2018-09-13
- Drug Name: Atractylodes lancea
- Inspection Finding: [Properties] [Content Determination] (Atractylodes lancea)
- Action Taken: The municipal (prefecture-level) food and drug administration bureau where the enterprise is located shall, in accordance with the relevant provisions of the "Drug Administration Law" and the "Regulations for the Implementation of the Drug Administration Law", investigate and punish the illegal acts of enterprises or units that produce, sell or use substandard drugs, disclose the results of the handling within three months, and report the relevant information to the provincial bureau in a timely manner.
- Summary: The Sichuan Provincial Food and Drug Administration issued a Drug Quality Bulletin on September 13, 2018, announcing findings from supervisory sampling inspections conducted across the province. These inspections aimed to enhance drug supervision and ensure public safety.

The bulletin disclosed that 21 batches of drugs were found to be substandard. The violations, identified across various manufacturers and product types including granules, capsules, and traditional Chinese medicine slices, primarily involved quality control deficiencies. Common issues included discrepancies in fill weight or quantity, unacceptable appearance, impurities, non-compliance with specific physical properties, and inaccurate content determination of active ingredients. Examples of affected companies include Guilin Ge Xian Weng Pharmaceutical Co., Ltd., Jiangxi Yaodu Renhe Pharmaceutical Co., Ltd., and Tonghua Wantong Pharmaceutical Co., Ltd., among others.

These inspections were conducted in accordance with the National Drug Sampling Management Measures and specific provincial requirements, referencing standards such as the Chinese Pharmacopoeia. In response to these findings, the Provincial Bureau mandated that municipal food and drug administrations investigate and address the illegal activities of the implicated production, sales, and usage units. Local authorities are required to publicize their handling results within three months and report back to the Provincial Bureau, ensuring accountability and adherence to drug administration laws and regulations.

Company: https://www.globalkeysolutions.net/companies/sichuan-jingzhong-traditional-chinese-medicine-pieces-co-ltd/4f6f764d-7635-42f2-ab3f-4f79c6c03c0a/